Skip to main content
Alphanox Co.,Ltd. logo

Alphanox Co.,Ltd. — Investor Relations & Filings

Ticker · 043100 ISIN · KR7043100007 KO Manufacturing
Open in API
Filings indexed 364 across all filing types
Latest filing 2021-03-05 Proxy Solicitation & In…
Country KR South Korea
Listing KO 043100

About Alphanox Co.,Ltd.

https://alphanox.co.kr/en/

Alphanox Co.,Ltd., formerly known as Solco Biomedical, is a global medical and healthcare group established in 1974. The company specializes in the development, manufacturing, and sale of advanced medical devices and health-promoting products. Its primary product lines include surgical instruments, orthopedic implants with a strong focus on spinal applications, and in-vitro diagnostic devices. In addition to its core medical offerings, Alphanox also produces healthcare products such as functional water and other health-promoting devices. The company is committed to improving quality of life through extensive research and development grounded in medical engineering and clinical results.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Solco Biomedical. It contains the meeting agenda, details on voting procedures (including electronic voting), and management's report on business activities and financial status ( 경영참고사항). This type of document is standard for proxy solicitation and shareholder meeting materials, which falls under the Proxy Solicitation & Information Statement category.
2021-03-05 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy/Voting Rights). It contains information regarding the solicitation of proxies for the Annual General Meeting (AGM), including the purpose of the solicitation, details about the proxy solicitor, and instructions for electronic voting. This is a standard regulatory document used to solicit shareholder votes for an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2021-03-05 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Solco Biomedical) regarding a significant change in financial structure (30% or more change in revenue or profit/loss). This is a standard disclosure requirement in the Korean stock market (KRX) for preliminary earnings announcements before the final audit report is published. Since it provides key financial highlights and performance metrics rather than the full annual report or a simple announcement of a report's availability, it falls under the Earnings Release (ER) category. FY 2020
2021-02-08 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the suspension of share registration (shareholder register closure) for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory notice of a corporate action. Given it is a standard regulatory announcement that does not fit into specific categories like dividend or share buyback, it falls under the general regulatory filing category.
2020-12-14 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the 26th fiscal period (2020) of Solco Biomedical Co., Ltd. It contains detailed financial statements, management discussion and analysis, and corporate governance information for the period ending September 30, 2020. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-16 Korean
기타시장안내(코스닥시장위원회 심의의결 결과 및 개선기간 부여 안내)
Delisting Announcement Classification · 100% confidence The document is a short regulatory notice from the Korea Exchange regarding the KOSDAQ Market Committee's decision to grant an improvement period to Solco Biomedical. It discusses listing status, improvement periods, and regulatory procedures. Since it is a regulatory announcement regarding market status and does not fit into specific categories like M&A or financial reports, it falls under the general regulatory filing category.
2020-09-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.